European regulatory authorities and pediatric labeling.
نویسنده
چکیده
Ethical Considerations Children should not be given medicines that have not been evaluated adequately for use in that age group. There is a responsibility, shared by applicants and the appropriate authorities, to ensure that children have timely access to safe and effective medicines that have accurate, scientifically justified prescribing information. Applicants are encouraged to investigate the safety and efficacy of a product in children, if it is likely to be of therapeutic benefit in this age-group, and to develop suitable formulation, even if use is likely to be small. However important a clinical trial may be to prove or disprove the value of a treatment, individual members of one or both of the groups—subject or control—can suffer injury as a result of inclusion in the trial, even if the whole community benefits. As with adults who participate in clinical trials and who understand the issues involved in giving their informed consent, consent should be obtained from the legal guardian of children in accordance with national legislation. Children should be fully informed about the trial in language and terms they understand and, if able, should personally sign and date the written informed consent. The child should be made aware of his/her rights to decline to participate. The child’s wish to be withdrawn from a study must be respected. These measures should be applied in conjunction with 1) part 4 of Directive 75/318/EEC, as amended, which requires “. . . details concerning patients who may be at increased risk”; the CPMP/ICH guideline for good clinical practice; and 3) the CPMP guideline on biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. These measures are intended to assist applicants with specific problems presented by medicinal product testing in children. The child should stand to obtain some direct benefit from the clinical trial, except under very specific conditions, although it is not appropriate to offer financial or other inducements to parents, guardians, or children to participate in clinical trials. However, they may receive reimbursement for their costs, including those for travel and subsistence.
منابع مشابه
Pediatric Melanoma and Drug Development
Importance-Pediatric melanoma occurs, albeit rarely. Should patients be treated by today's medical standards, or be subjected to medically unnecessary clinical studies? Observations-We identified international, industry-sponsored pediatric melanoma studies triggered by regulatory demands in www.clinicaltrials.gov and further pediatric melanoma studies demanded by European Union pediatric invest...
متن کاملIs European M&a Regulation Protectionist?*
Why do regulatory authorities scrutinise mergers and acquisitions? The authorities themselves claim to be combating monopoly power and protecting consumers. But the last two decades of empirical research has found little supporting evidence for such motives. An alternative is that M&A regulation is actually designed to protect privileged firms. We provide a test of protectionism by studying whe...
متن کاملPediatric exclusivity and other contemporary regulatory changes: impact on pediatric drug study, labeling and safety
Historically, most drugs have been used ‘off-label’ in children due to a lack of specific information on dosing, safety and efficacy. This practice risks adverse events, leading to serious public health consequences. Regulatory changes have attempted to address such issues by mandating and incentivizing the study of drugs in children. By all accounts, these regulatory changes have been enormous...
متن کاملSummary of a workshop on regulatory acceptance of (Q)SARs for human health and environmental endpoints.
The "Workshop on Regulatory Use of (Q)SARs for Human Health and Environmental Endpoints," organized by the European Chemical Industry Council and the International Council of Chemical Associations, gathered more than 60 human health and environmental experts from industry, academia, and regulatory agencies from around the world. They agreed, especially industry and regulatory authorities, that ...
متن کاملPediatric oncology: regulatory initiatives.
The majority of children with cancer receive therapy as participants in clinical research protocols coordinated by national pediatric cooperative groups. One of the highest priorities of these groups is the development of novel therapies. Due to differences in the biology of pediatric and adult tumors and in physiology between adults and children, it is usually necessary to evaluate the safety ...
متن کاملRegulation, the Regulatory State and European Politics
The term ‘regulatory state’ entered the vocabulary of students of European Politics over twelve years ago with the publication, in West European Politics, of Giandomenico Majone’s seminal ‘The rise of the regulatory state in Europe’ (Majone 1994). Underlying Majone’s argument was the diagnosis of two key trends, one being an overall shift towards the use of legal authority or regulation over th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Pediatrics
دوره 104 3 Pt 2 شماره
صفحات -
تاریخ انتشار 1999